Kathy Hibbs, J.D. serves as a member of the Board of Directors of Standard BioTools Inc. She is an accomplished healthcare technology executive and active board member with more than two decades of expertise in healthcare and genomics. ln May of 2024, she retired as the Chief Administrative Officer of 23andMe and prior to that role as the Chief Legal and Regulatory Officer of 23andMe from 2014 to 2022, where she led its complex legal operations and regulatory affairs. She is globally recognized for her effectiveness, having successfully pioneered the first FDA clearance for over-the-counter genetic testing. Regularly recognized as one of the Bay Area’s most influential women by both the San Francisco Business Times and Silicon Valley Business Journal, Kathy is ranked by Chambers as among the most influential general counsel in the US. She sits on the board of Cadex Genomics, Inc. and previously served on the board of directors of Decipher Biosciences, Inc. During her 15 years as an executive officer and corporate secretary for two public biotechnology companies, Genomic Health, Inc. (NASDAQ: GHDX), Monogram Biosciences, Inc. (NASDAQ: MGRM) and in the leadership team of Varian Medical Systems, Inc. (NASDAQ: VAR) involved in legal, business development and compliance matters, Kathy developed her passion for personalized medicine and the power of innovation to improve the lives of patients. Kathy graduated summa cum laude from the University of California, Riverside, where she received her J.D. from Hastings College of Law.